Original Article

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Gelfand JM, MD MSCE1,2, Armstrong AW, MD MPH3, Bell S, PhD4, Anesi GL, MD MSCE MBE2,5, Blauvelt A, MD MBA6, Calabrese C, DO7, Dommasch ED, MD MPH8, Feldman SR, MD PhD9, Gladman D, MD FRCPC10,11, Kircik L, MD12,13, Lebwohl M, MD12, Lo Re V III, MD MSCE2,14, Martin G, MD15, Merola JF, MD MMSc16, Scher JU, MD17, Schwartzman S, MD16, Treat JR, MD19, Van Voorhees AS, MD20, Ellebrecht CT, MD1, Fenner J, MD12, Ocon A, MD PhD21, Syed MN, MBBS1, Weinstein EJ, MD14, Smith J, BS4, Gondo G, MA4, Heydon S, MA4, Koons S, BS4, and Ritchlin CT, MD MPH 21

1 Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
2 Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
3 Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
4 National Psoriasis Foundation, Portland OR, USA
5 Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
6 Oregon Medical Research Center, Portland, OR, USA

This is the author's manuscript of the article published in final edited form as:

24. Department of Rheumatology and Immunology, Cleveland Clinic, OH, USA
25. Department of Dermatology, Harvard Medical School, Boston, MA, USA
26. Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA
27. Krembil research Institute, Toronto Western Hospital, Ontario, Canada
28. University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
29. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
30. Indiana University Medical Center, Indianapolis, IN, USA
31. Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
32. Dermatology Associates, Maui, HI, USA
33. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
34. Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA
35. Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
36. Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
37. Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
38. Division of Allergy, Immunology, & Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA
**Corresponding Author:** Joel M. Gelfand; Department of Dermatology; 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine Philadelphia, PA, 19104; Joel.Gelfand@pennmedicine.upenn.edu

**Funding sources:** None

**Conflicts of interest:**

Dr Anesi has pending fees from UpToDate for authoring COVID-19 clinical reference material. Research time is supported by AHRQ K12HS026372.

Dr Armstrong has served as a research investigator and/or scientific advisor to Leo, AbbVie, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, BMS, Sanofi, Regeneron, Dermira, and Modmed.

Dr Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie.

Dr. Bell, Gondo, Heydon, Koons, Smith are employees of the National Psoriasis Foundation

Dr Calabrese is a speaker for Sanofi-Regeneron and consultant for AbbVie
Dr. Feldman received research, speaking and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. Dr Feldman also consults for others through Guidepoint Global, Gerson Lehrman and other consulting organizations. He is the founder and majority owner of www.DrScore.com. He is also a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.

Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), and Sanofi and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer Inc, and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.

Dr Gladman is a consultant for Abbvie, Amgen, BMS, Galapagos, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, UCB. Grants: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB
Dr. Kircik has served either as an investigator, consultant, or speaker for Abbvie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol-Myers Squibb, Boehringer Ingelheim, Cellceutix, Celgene, Coherus, Dermavant, Dermira, Eli Lilly, Leo, MC2, Maruho, Novartis, Ortho Dermatologics, Pfizer, Dr Reddy's, Sun Pharma, UCB, Taro, Xenopoint.

Dr Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, Leo Pharmaceuticals, Ortho Dermatologics, Pfizer, and UCB, Inc. and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica.

Dr. Martin is a consultant for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly, LEO, Ortho Dermatologic, Pfizer, UCB and a Scientific Advisor for Almirall, Athenex, Bristol-Meyers Squibb, Celgene, Eli Lilly, Janssen, LEO, Ortho Dermatologic, Pfizer, UCB

Dr Merola is a consultant and/or investigator for Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sun Pharma, Pfizer, EMD Sorono

Dr Ritchlin reports personal fees from AbbVie, Amgen, Janssen, Novartis, UCB, Boehringer Ingelheim, as well as grants from Amgen, UCB and Abbvie outside the submitted work.
Dr. Schwartzman is a speaker for AbbVie Genentech Janssen Lilly Novartis Pfizer UCB, owns stock in AmgenBoston scientific Gilead Medtronic Pfizer, is a consultant for AbbVie Myriad Janssen Gilead Lilly Novartis UCB,is a scientific advisory board member for Myriad, and is a Board Member of the National Psoriasis Foundation.

Dr Scher is a consultant for UCB, Janssen, Abbvie, Pfizer, Novastis, Sanofi

Dr Syed is supported by a grant from Pfizer

Dr. Van Voorhees has been an investigator for Celgene, Lilly and AbbVie. She has been an advisor/consultant for the following companies: AbbVie, Allergan, Astra Zeneca, Celgene, Dermira, Merck, Novartis, Pfizer, UCB, Valeant

Drs. Weinstein, Ellebrecht, Ocon, Fenner, Treat, Dommasch, and Lo Re, have no conflicts of interest to disclose

Manuscript word count (max 2500): 2495

Abstract word count (max 200) : 198
Capsule summary word count (max 50) : 48

References: 142

Tables: 2

Supplementary tables: 9

Supplementary material: 1

Keywords: Psoriasis, Psoriatic arthritis, COVID-19, SARS-CoV-2, Biologics
Abstract:

Objective: To provide guidance about management of psoriatic disease during the COVID-19 pandemic.

Study Design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.

Results: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus.

Limitations: The evidence behind many guidance statements is limited in quality.

Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower
their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19.

The guidance is intended to be a living document that will be updated by the TF as data emerge.

**Capsule Summary:**

- The NPF COVID-19 Task Force produced 22 guidance statements to promote optimal management of psoriatic disease during the pandemic.

- Shared decision making is recommended as is adherence to evidence-based recommendations when available. The guidance statements will be updated when necessary in accordance with rapidly evolving science of COVID-19.
Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), a single stranded RNA virus that binds to the ACE-2 receptor and causes illness called COVID-19, has precipitated devastating personal, economic and societal repercussions worldwide.\textsuperscript{1-4} SARS-CoV-2 usually causes a mild, self-limited illness, but about 15\% of affected individuals have a more severe, sometimes life-threatening course, with the risk of poor outcomes increasing with age and comorbidities.\textsuperscript{5-7} Diffuse alveolar damage and acute respiratory distress syndrome are the most common presentations in severe COVID-19. Additionally, thrombo-embolic events along with direct and indirect viral-induced injury may target the skin, gastrointestinal tract, kidney, heart and brain with devastating consequences.\textsuperscript{8-10}

The type 1 interferon response, required to clear the virus, is often insufficient in the early phase of SARS-CoV-2 infection but a delayed persistent elevation may develop as the illness progresses.\textsuperscript{11} Profound dysregulation of innate and acquired immunity can occur with more severe COVID-19, including significant lymphopenia as a direct result of viral-induced apoptosis and necrosis of lymphocytes in the spleen and lymph nodes.\textsuperscript{12} The persistent interferon response can result in systemic hyperinflammation (a.k.a., cytokine storm).\textsuperscript{13,14} Several of the cytokines elevated in severe COVID-19 patients (TNF, IL-6, and IL-17) are also elevated in patients with psoriatic disease.\textsuperscript{15-17}

The current model of COVID-19 is that immune suppression in early infection may be harmful by allowing uncontrolled SARS-CoV-2 replication and dissemination, but may be helpful in severe illness by limiting organ damage from a dysregulated hyperimmune response\textsuperscript{18}. Many treatments used for
Psoriatic disease directly or indirectly impact immune pathways involved in COVID-19.\textsuperscript{19-22} Patients and providers are concerned about the safety of immunomodulating agents in the setting of the COVID-19 pandemic. These concerns are particularly relevant given that many of the comorbidities associated with psoriasis and psoriatic arthritis (PsA), including obesity, diabetes and cardiovascular disease, are risk factors for the development of severe COVID-19.\textsuperscript{23, 24} To address the questions posed by patients and providers, the National Psoriasis Foundation (NPF) commissioned a COVID-19 task force (TF) to develop scientifically-based guidance that promotes optimal management of psoriatic disease during the pandemic.
METHODS

See online supplement for detailed methods.

Establishment of Task Force

The COVID-19 TF includes 18 physicians with a variety of expertise relevant to decision-making in the pandemic from different geographical areas within the United States and Canada, many of whom have frontline experience managing a surge of COVID-19 patients (E Table 1). The TF was supplemented by non-voting members which include 4 trainees in dermatology, rheumatology, and infectious diseases, 1 post-doctoral fellow in epidemiology, as well as senior staff from the NPF.

Evidence Synthesis

The TF co-chairs completed weekly literature searches for COVID-19 in relation to psoriatic disease. TF members also recommended papers of broad importance to COVID-19 related to its basic biology, epidemiology, and treatment. Additional sources of data were obtained from the CDC, WHO, FDA, and NIH.

Development of Clinical Questions

The TF met every 2 weeks to discuss the developments in the literature and clinical experience. Clinical questions relevant to the psoriatic disease community were iterated and informed by questions received by the NPF from the broader patient and clinical community. The questions were subdivided into 5 categories and work groups with balanced expertise were formed. Each work group
of the TF convened to draft responses to the clinical questions based on the available evidence. These responses were reviewed and drafted into guidance statements.

**Modified Delphi Process**

The guidance statements were presented to the 18 TF members using a modified Delphi process including 2 rounds of voting with discussion in between. The Delphi approach was based on the RAND appropriateness method, which has been extensively validated.\(^{25-31}\)

TF members were asked to report their level of agreement anonymously with each guidance statement on a scale of 1-9. A rating of 1 corresponded to “complete disagreement,” 5 corresponded to “uncertain or neutral,” and 9 corresponded to “complete agreement.” The members were able to provide anonymous written comments. Median vote ratings of 1–3, 4–6, and 7–9 were defined \textit{a priori} as disagreement, uncertainty/neutral, and agreement, respectively. Panel consensus was determined to be “low” when \(\geq 5\) votes fell into the 1–3 rating range with \(\geq 5\) votes concurrently falling into the 7–9 rating range. Consensus was interpreted as “high” if all 18 votes fell within a single tertile, with all other combinations considered as “moderate” levels of consensus. The results were analyzed by the NPF with an independent analysis of the data by a non-voting member of the TF, which yielded identical results.
RESULTS:

The TF Delphi was completed over a 2 week period (E Table 2). Five categories of questions were explored (E Table 3) with 100% complete voting on 22 guidance statements (Table 4 & E-Table 4). The median was within the category of agreement for all statements, with the number of votes outside the range of agreement being only 1 or 2 for statements where agreement was not unanimous. All guidance statements were recommended, 9 with high consensus, and the remainder with moderate consensus.

Category 1: What are the effects of psoriatic disease itself on SARS-CoV-2 infection and COVID-19 illness?

Patients with psoriatic disease appear to have similar rates of infection with SARS-CoV-2 and COVID-19 outcomes\(^32-36\) as the general population (Guidance 1.1). However, uncertainty remains regarding this question. First, a few reports suggest that psoriasis patients may be more prone to infection with COVID-19 or have worse outcomes.\(^37-39\) For example, a United Kingdom study with over 17 million patients found a small but statistically increased risk of death from COVID-19 (fully adjusted Hazards Ratio (HR) 1.19 [95% CI 1.11-1.27]) in individuals with either psoriasis, rheumatoid arthritis or lupus.\(^38\) It is unknown from this study the degree to which the observed finding is driven by psoriasis, its severity, or treatment. Additionally, patients with psoriatic disease may be prone to
thrombotic complications that can also occur in COVID-19.\textsuperscript{40-54} There was unanimous agreement that severity of COVID-19 is driven by risk factors such as older age and comorbidities (Guidance 1.2).\textsuperscript{32, 35, 36, 38, 55-58} Psoriatic disease—particularly severe psoriasis—is associated with many of the comorbidities that drive COVID-19 mortality.\textsuperscript{44, 48, 59}

**Category 2:** What are the effects of psoriasis or psoriatic arthritis treatment on SARS-CoV-2 infection and COVID-19 illness?

The existing literature suggests that treatments for psoriasis and/or PsA do not meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes (Guidance 2.1)\textsuperscript{36, 60-86}. Cyclosporine, the most broadly immunosuppressive of psoriasis treatments, was not found to alter risk of COVID-19 in 130 patients in Italy with psoriasis or atopic dermatitis (2 became infected with SARS-CoV-2 and recovered without hospitalization).\textsuperscript{70} This study lacked a comparison group and is too small to reach definitive conclusions. One study suggested that psoriasis patients on biologics were more likely to be hospitalized for COVID-19 but did not adjust for risk factors known to drive poor COVID-19 outcomes.\textsuperscript{87}

The rheumatology literature also suggests that treatments used for psoriatic disease (such as TNF inhibitors and methotrexate) do not negatively impact COVID-19\textsuperscript{88-91} with one large registry (600 case reports from 40 countries) finding that TNF inhibitors are associated with a reduced adjusted odds of COVID-19 hospitalization compared to patients with rheumatic conditions not treated with TNF inhibitors.\textsuperscript{91} Similarly, adverse effects of TNF inhibitors on COVID-19 were not observed in large
registries of IBD patients. Small case series have reported poor COVID-19 outcomes in patients on JAK inhibitors for PsA and secukinumab for ankylosing spondylitis; however, these isolated reports could be due to selection bias, chance, or underlying comorbidity. By contrast, an analysis of about 1400 patients from the rheumatology, gastroenterology, and dermatology literature concluded that biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe COVID-19 outcomes.

Given these data, patients who are not infected with SARS-CoV-2 should continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases (Guidance 2.2). Nevertheless, the existing literature is largely based on small case series or large registries of spontaneous reports and therefore shared decision-making between clinician and patient is recommended (Guidance 2.2, 2.4, 2.5). By contrast, studies in the rheumatology and gastroenterology literature have observed that chronic use of oral corticosteroids is associated with worse COVID-19 outcomes (i.e., hospitalization, or a composite outcome of ICU admission, ventilator use, and/or death). Chronic systemic corticosteroids should be avoided, if possible, for the management of psoriatic arthritis (guidance 2.3).

**Category 3:** How should medical care be delivered to patients with psoriatic disease to lower their risk of infection with SARS-CoV-2 while still ensuring quality of care?

The pandemic has disrupted the ability of patients and providers ability to meet in person due to personal protective equipment shortages, measures implemented to lower risk of SARS-CoV-2
transmission, and patients’ personal and economic hardships. Patients express concern about being exposed to SARS-CoV-2 in the clinical setting either directly or indirectly (i.e., on public transportation). Telemedicine can achieve similar outcomes for psoriasis patients compared to in person care with a dermatologist; however, limited information available on management of psoriatic arthritis with telemedicine. Telemedicine should be considered when pandemic conditions limit in-person visits (Guidance 3.1). However, there are limitations of telemedicine, and therefore some patients should be evaluated in person (Guidance 3.2). Office-based phototherapy remains an important option for patients with psoriasis (Guidance 3.3, Table 5).

**Category 4: What should patients with psoriatic disease do to protect themselves from becoming infected with SARS-CoV-2?**

Patients should be advised to follow measures that prevent infection with SARS-CoV-2 (Guidance 4.1, E-Table 6). These prevention measures should be followed at work (Guidance 4.2) and school (Guidance 4.3). In cases where measures to prevent transmission of SARS-CoV-2 at work or school cannot be maintained, shared decision-making is recommended to determine if specific accommodations are medically necessary (Guidance 4.2 and 4.3). Psoriasis, even when involving the face or hands, is not a contraindication to face coverings and hand washing respectively, and a variety of approaches can be applied to mitigate skin irritation (E-Table 7). Patients with psoriatic disease should receive the seasonal inactivated (e.g. killed) influenza vaccine, which is of special importance to individual and public health during the COVID-19 pandemic (Guidance 4.4).
Providers may consider temporary discontinuation of methotrexate for 2 weeks after flu immunization in order to improve the immunogenicity of seasonal influenza vaccine.\textsuperscript{112}

**Category 5:** What should patients with psoriatic disease do if they become infected with SARS-CoV-2?

Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their symptoms (E-Table 8), discuss management of their psoriatic disease treatments with their health care providers, and should be prescribed and adhere to evidence-based COVID-19 treatments, if available (Guidance 5.1, 5.2).\textsuperscript{86,113-115} The mortality benefit of initiation of corticosteroids in patients with severe COVID-19 outweighs the risks of potentially precipitating a psoriasis flare, and therefore, acute systemic corticosteroids are not contraindicated for the management of COVID-19 in patients with psoriatic disease (Guidance 5.3).\textsuperscript{115-117} Based on limited available data, and to be consistent with prescribing information, it may be prudent to hold treatments that target the immune system in the setting of suspected or confirmed SARS-CoV-2 infection, but the final decision needs to be determined on a case by case basis. Consistent with guidance from the FDA and the American College of Physicians, the use of hydroxychloroquine or chloroquine is not recommended to prevent or treat COVID-19 in patients with psoriatic disease outside of a clinical trial (guidance 5.4).\textsuperscript{118-130} Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare of psoriasis, which may occur due to discontinuation of psoriasis treatments, treatment of COVID-19 with anti-malarial drugs, or due to triggering of inflammation as part of COVID-19 illness (Guidance 5.6)\textsuperscript{129,131-133}. 
Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance on home isolation and discuss with their healthcare providers when they can end home quarantine (Guidance 5.7, E-Table 9). In the event someone with psoriatic disease has close contact (E-Table 10) with an individual with suspected or confirmed SARS-CoV-2 infection, they should quarantine for 14 days after the last contact, as per CDC guidelines (guidance 5.8). The decision regarding continuing or holding psoriasis treatments during a period of quarantine should be individualized on a case-by-case basis between patient and provider.

Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis (guidance 5.5). The persistence of one or more symptoms of COVID-19, such as fatigue or joint pain, beyond the acute phase of the illness can occur, and may complicate the decision to restart psoriasis or PsA medications. Therefore shared decision-making is recommended (Guidance 2.5).
DISCUSSION

The NPF COVID19 TF guidance statements serve to promote optimal management of psoriatic disease during the pandemic. There are several strengths to the approach taken. First, the TF assembled is a geographically diverse team with expertise in adult and pediatric dermatology, rheumatology, critical care, infectious diseases, epidemiology, and basic and translational immunology with experience managing surges in COVID-19. The TF also includes trainees in dermatology, rheumatology and infectious disease who are on the frontlines managing COVID-19 patients as well as senior staff from the NPF who are in touch daily with patients and providers worldwide whose questions are brought to the TF. Second, we have established a robust process for staying up to date with the latest literature relevant to COVID-19 and the management of psoriatic disease resulting in the dissemination and evaluation of hundreds of peer reviewed publications by the TF. Third, a validated Delphi approach enabled transparency and reproducibility of our process for evaluating consensus statements.\textsuperscript{25-31}

Several limitations are acknowledged. First, the TF did not formally grade the strength of our recommendations.\textsuperscript{142} With the exception of guidance statements 4.4, 5.2, and 5.4, which are based on large scale randomized controlled trials, the evidence behind many of the guidance statements was often limited in quality. For example, studies evaluating the safety of treatments for psoriasis and psoriatic arthritis in the setting of COVID-19 involve small case series or large collections of case reports and thus should be considered preliminary. Large scale, longer term, population-based
studies, with appropriate comparator groups, adjustment for relevant confounding variables, and complete ascertainment of clinically important COVID-19 outcomes are urgently needed. Second, the guidance is not intended to be proscriptive nor comprehensive. The ultimate judgment regarding how these recommendations should be followed is best left with the treating clinician and the patient in light of the circumstances presented by the individual patient, and the variability and biological behavior of the disease and therapeutics. Third, the TF does not have global representation of experts or direct inclusion of patients.

The guidance statements are intended to be part of a “living” document that will be updated and amended when necessary by the rapidly evolving science of COVID-19. Readers are encouraged to visit https://www.psoriasis.org/covid-19-resource-center regularly for the latest guidance from the TF in order to promote optimal care and outcomes for patients with psoriatic disease during the pandemic.
<table>
<thead>
<tr>
<th>Guidance #</th>
<th>Guidance Statement</th>
<th>Level of Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>It is not known with certainty if having psoriatic disease meaningfully alters the risks of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course of COVID-19 illness. Existing data, with some exceptions, generally suggest that patients with psoriasis and/or psoriatic arthritis have similar rates of SARS-CoV-2 infection and COVID-19 outcomes as the general population.</td>
<td>Moderate</td>
</tr>
<tr>
<td>1.2</td>
<td>The likelihood of poor outcomes from COVID-19 is driven by risk factors such as older age and comorbidities such as chronic heart, lung, or kidney disease and metabolic disorders such as diabetes and obesity. Patients with psoriatic disease are more prone to these comorbidities, particularly in those with more severe disease.</td>
<td>High</td>
</tr>
<tr>
<td>2.1</td>
<td>It is not known with certainty if treatments for psoriasis and/or psoriatic arthritis meaningfully alter the risks of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course of COVID-19 illness. Existing data generally suggest that treatments for psoriasis and/or psoriatic arthritis do not meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes.</td>
<td>Moderate</td>
</tr>
<tr>
<td>2.2</td>
<td>It is recommended that patients who are not infected with SARS-CoV-2 continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared decision-making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see guidance 2.5 for definition of shared decision making).</td>
<td>High</td>
</tr>
<tr>
<td>2.3</td>
<td>Chronic systemic corticosteroids should be avoided if possible for the management of psoriatic arthritis. If patients require chronic systemic corticosteroids for management of psoriatic arthritis, the dose should be tapered to the lowest dose necessary to achieve the desired therapeutic effect. Chronic systemic corticosteroid use for the treatment of psoriatic disease at the time of acute infection with SARS-CoV-2 may be associated with worse outcomes from COVID19 illness. It is important to note, however, that corticosteroids may improve outcomes for COVID19 when initiated in hospitalized patients requiring oxygen treatment.</td>
<td>High</td>
</tr>
<tr>
<td>2.4</td>
<td>Individuals newly diagnosed with psoriasis and/or psoriatic arthritis or who are currently not receiving treatment should be aware that untreated psoriatic disease is associated with serious impact on physical and emotional health, and in the case of psoriatic arthritis, can lead to permanent joint damage and disability. Shared decision making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see guidance 2.5 for shared decision making).</td>
<td>High</td>
</tr>
<tr>
<td>2.5</td>
<td>Providers recommend shared decision making with patients. Shared decision making between clinician and patient should be guided by several factors, including the potential benefits of treatment, the activity of skin and/or joint disease and response to previous therapies, as well as the patient’s underlying risk for poor COVID19 outcomes, and ability to maintain measures to prevent infection with SARS-CoV-2 such as hand hygiene, wearing of masks, and physical distancing as required by</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
pandemic conditions. A review of known benefits of treatment accompanied by acknowledgment of the uncertainty related to the COVID19 pandemic and a discussion of a patient’s individual circumstances and preferences should guide decision making.

| 3.1 | Telemedicine should be offered to manage patients wherever possible when local restrictions or pandemic conditions limit the ability for in-person visits. The following patients can be managed with telemedicine: Patients who are clinically stable and previously started on psoriatic disease treatment. Patients requiring a follow-up visit and refills for medication. New patients without timely access to in-person visits. Patients diagnosed with COVID-19 who are experiencing a significant flare. If telemedicine visits become inadequate to monitor patients’ disease progress or manage new or evolving symptoms or signs of skin and joint disease, clinicians and patients should consider in-person visits. | Moderate |

| 3.2 | The following patients should be considered for in-person care if pandemic conditions allow (i.e., the clinical practice is open to see patients in person): Patients at risk for melanoma and non-melanoma skin cancer should be seen in person at a frequency consistent with standard of care for a full skin examination. New patients establishing care. Patients experiencing unstable psoriatic disease/flare. Patients requiring a thorough skin/or joint examination and a full physical examination for rheumatology patients. | Moderate |

| 3.3 | Providers recommend the recent guidelines published by Lim et al. on how to optimize safety of office phototherapy for the patients and staff in the setting of the pandemic. See Table 5 for details. | High |

| 4.1 | Patients should be advised to follow measures that prevent infection with SARS-CoV-2. These preventative measures include: To practice good hand hygiene, to maintain physical distancing from non-household members, and to wear a face covering of the nose and mouth when indoors (except in their own home), and when outdoors, but unable to maintain physical distancing. Face coverings should not be used in children under 2 years old due to risk of suffocation. See E Table 6 for details. | High |

| 4.2 | Patients with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 in the workplace. If the work place environment does not allow for maintenance of prevention measures, a shared decision-making process between the patient and his/her clinician is recommended to determine if specific accommodations are medically necessary, especially for individuals whom, due to age or underlying health conditions, are at especially high risk for poor COVID19 outcomes. | Moderate |

| 4.3 | Youth with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 while at school. These measures include maintaining 6 feet of physical distancing, consistently wearing masks if over the age of 2 years, and washing hands frequently. If the school environment is unable to ensure these prevention measures or families believe their child may not be able to adhere to these practices, we encourage discussion with the patient, caregivers, and his/her clinician to collectively develop a learning plan in the best interest and safety of the child. | High |

| 4.4 | Patients with psoriatic disease should receive the seasonal inactivated (e.g. killed) influenza vaccine when it becomes available. While this vaccine will not protect against SARS-CoV-2, influenza vaccine lowers the risk of infection from seasonal influenza, which is of special importance to individual and public health during the COVID-19 pandemic. | High |
COVID-19 pandemic. Patients taking systemic medications for psoriasis or psoriatic arthritis should discuss the timing of influenza vaccination with respect to their systemic psoriatic medications with their health care provider in order to optimize the response to the influenza vaccine.

| 5.1 | Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their symptoms and discuss the management of their treatments with their health care providers. | Moderate |
| 5.2 | Patients with psoriatic disease who become infected with SARS-CoV-2 should be prescribed and adhere to evidence-based COVID-19 therapies. Evidence-based therapies should be used, currently including supportive care for patients with mild disease, as well as dexamethasone (systemic corticosteroids) and remdesivir treatment, if available, for hospitalized patients requiring supplemental oxygen. The care of the hospitalized patient should include consultation with rheumatologists, dermatologists, and/or infectious disease specialists as medically necessary. | Moderate |
| 5.3 | Systemic corticosteroids for the management of COVID-19 in patients with psoriatic disease are not contraindicated and should not be withheld due to the concern of potentially flaring psoriasis upon withdrawal of corticosteroids when evidence demonstrates the effectiveness for treating COVID-19 illness. | Moderate |
| 5.4 | Hydroxychloroquine or chloroquine are not recommended for the prevention or treatment of COVID-19 in patients with psoriatic disease outside of a clinical trial. Cases of psoriasis flare have been reported in patients on anti-malarial medications, but the clinical significance is not well understood. | High |
| 5.5 | Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis. Most patients can restart psoriasis and/or psoriatic arthritis treatments after complete resolution of COVID-19 symptoms. In those who have had a severe hospital course, shared decision making made on a case-by-case basis is recommended. | Moderate |
| 5.6 | Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare of psoriasis based on case reports. The clinical significance of the risk of COVID-19 flaring psoriasis is not known. | Moderate |
| 5.7 | Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance on home isolation and discuss with their healthcare providers when they can end home isolation. We recommend waiting a minimum of 10 days after COVID-19 symptom onset, along with fever resolution for 24 hours without antipyretics and improvement in other symptoms, before ending home isolation and returning to work, as patients are unlikely to be infectious after this point. In patients with severe cases of COVID-19 or when psoriasis patients are on medications with immunosuppressive effects, we recommend a case-by-case approach to determining the length of home isolation. | Moderate |
| 5.8 | Patients with close contact to someone with SARS-CoV-2 infection should quarantine themselves for 14 days after the last contact and discuss the management of their psoriatic disease treatment with their medical provider(s). | Moderate |

*SD: Standard Deviation **IQR: Interquartile Range
Table 5: Methods to Reduce Risk of SARS-CoV-2 Transmission During Delivery of Office-Based Phototherapy

<table>
<thead>
<tr>
<th><strong>Patient Protocol</strong></th>
<th><strong>Staff Protocol</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Screened for signs and symptoms of COVID-19 before entering the unit, understanding that treatment will be denied to symptomatic patients.</td>
<td>• Schedule patients approximately 30 minutes apart per booth</td>
</tr>
<tr>
<td>• Attend the phototherapy appointment alone. Minors can be accompanied by a guardian, given all safety protocols are observed</td>
<td>• Practice physical distancing, particularly in waiting area, with seats 6 feet apart.</td>
</tr>
<tr>
<td>• Apply hand sanitizer upon entering and leaving the unit.</td>
<td>• Wear a mask, eye protection, and apply hand sanitizer before and after each patient encounter.</td>
</tr>
<tr>
<td>• Patient provided with goggles, must sanitize them thoroughly, according to manufacturer's instruction</td>
<td>• Avoid turning on the fan of the phototherapy unit if possible; if need be, treatment can be fractionated to avoid excessive heat build-up in the unit</td>
</tr>
<tr>
<td>• Wear a mask, unless phototherapy treatment of the face is required</td>
<td>• Disinfect high-touch surfaces in the changing area after each patient</td>
</tr>
<tr>
<td>• Practice physical distancing</td>
<td>• Disinfect high-touch area of the phototherapy equipment in between patients</td>
</tr>
<tr>
<td></td>
<td>• Provide patients with disposable bags to store personal items</td>
</tr>
<tr>
<td></td>
<td>• Provide goggles to patients if need be; ensuring they are sanitized thoroughly and stored in an</td>
</tr>
<tr>
<td>individual bag</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Lim et al.106
Abbreviations and Acronyms

- SARS COV-2: Severe Acute Respiratory Coronavirus 2
- COVID-19: Coronavirus disease 2019
- IL: InterLeukin
- TNF: Tumor Necrosis Factor
- PsA: Psoriatic Arthritis
- TF: Task Force
- NPF: National Psoriasis Foundation
- IBD: Inflammatory Bowel Disease
- CDC: Centers for Disease Control
- WHO: World Health Organization
- FDA: Food and Drug Administration
- NIH: National Institutes of Health
- HR: Hazards Ratio
- JAK inhibitor: Janus Kinase Inhibitor
- SD: Standard Deviation
- IQR: Inter Quartile Range
Acknowledgements: The authors thank Monika Goyal, MD MSCE for her expert input on guidance statement.

References


105. Teledermatology tool kit.


108. How to Protect Yourself & Others: Center for disease control and prevention; 2020.


118. U.S. Food & Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. 2020, July 1.


140. Centers for Disease Control and Prevention. When to quarantine. 2020, August 3.


**Supplemental Methods and Tables:**

Gelfand , Joel (2020), “Suppl Tables”, Mendeley Data, V2, doi: 10.17632/w5m8jf94m8.2

Gelfand, Joel (2020), “Supplementary Tables and Methods”, Mendeley Data, V2, doi: 10.17632/x4mxnjmc76.2

Gelfand, Joel (2020), “Supplemental Table E-4”, Mendeley Data, V2, doi: 10.17632/n78m9f3cpr.2

Gelfand, Joel (2020), “Supplementary Table E-1-3”, Mendeley Data, V1, doi: 10.17632/2cbs7r7z72.1
Capsule Summary:

- The NPF COVID-19 Task Force produced 22 guidance statements to promote optimal management of psoriatic disease during the pandemic.
- Shared decision making is recommended as is adherence to evidence-based recommendations when available. The guidance statements will be updated when necessary in accordance with rapidly evolving science of COVID-19.